Meeting
2016 ASCO Annual Meeting
Overall survival in patients with glioblastoma before and after bevacizumab approval.
Authors
Derek Richard Johnson
Mayo Clinic, Rochester, MN
Derek Richard Johnson , Antonio Marcilio Padula Omuro , Arliene Ravelo , Nicolas Sommer , Annie Guerin , Raluca Ionescu-Ittu , Alexander R Macalalad , Sherry Shi , Joon H. Uhm
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2062)
DOI
10.1200/JCO.2016.34.15_suppl.2062
Abstract #
2062
Poster Bd #
249
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Blood baseline neutrophil count to predict bevacizumab efficacy in glioblastoma.
First Author: Aurelie Bertaut
Poster
2015 ASCO Annual Meeting
Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102).
First Author: Vinay K. Puduvalli
Poster
2015 ASCO Annual Meeting
The role of salvage radiation in recurrent glioblastoma after bevacizumab failure.
First Author: Nehaw Sarmey
Poster
2014 ASCO Annual Meeting
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.
First Author: Ulrich Herrlinger